24th-26th June, 2025 | Amsterdam, Netherlands

www.neoantigen-summit.com

SAVE €100 BY REGISTERING BY MONDAY, 23RD JUNE



8th Annual

International Neoantigen Summit

Advancing Cancer Treatment with Durable, Effective Neoantigen Vaccines & Therapies

Drive Your Discovery & Pre-Clinical Pipelines Into Robust Clinical Candidates by Improving Immune Response, Clinical Efficacy & Cost of Cancer Vaccines & Targeted Therapies

Expert Speakers Include:

Robbert Spaapen
Associate Director
AstraZeneca

Maurizio Ceppi
Chief Scientific Officer
Transgene

Ulrike Gnad-Vogt
Senior Vice President, Clinical Development
CureVac

Morena D'Alise
Senior Vice President, Immunology
Nouscom

Nermeen Varawalla
Chief Medical Officer
Scancell

Marie-Laure Santiago Raber
Chief Scientific Officer
AMAL Therapeutics

Proud to Partner With:

Personalis · ALMAC · intavis Peptide Services · BCN peptides · NEC · biOmay · Alithea bio

+44 (0)20 3141 8700 info@hansonwade.com
www.neoantigen-summit.com

hansonwade

Welcome to the 8th International Neoantigen Summit

8th Annual International Neoantigen Summit
24th-26th June | Amsterdam, Netherlands

2024 saw a wealth of clinical progression with **Nouscom**, **CureVac**, **Transgene** and other pioneering companies paving the way for neoantigen-based vaccines and therapies to become tolerable, durable medicines to effectively treat cancer.

Ready to unite the global neoantigen community, the **8th International Neoantigen Summit 2025** returns to Amsterdam to address key challenges in the **discovery**, **translation,** and **clinical development** of safe and cost-effective neoantigen therapies and vaccines to attract investors and ultimately improve the health of patients.

Join industry leaders from the likes of **AstraZeneca**, **Geneos Therapeutics**, **Evaxion Biotech** & **GSK,** and many more at this end-to-end meeting, driving innovation in neoantigen cancer vaccines and cell therapies. As the potential to deliver safe, efficacious personalised or off-the-shelf therapeutic options to patients increases, this is your chance to collaborate and accelerate the translation of neoantigen-based therapies from discovery to clinical success.

New and improved in 2025, hear first-hand from world-class biopharma experts as they share data-driven insights into:

- The **latest clinical learnings** to address bottlenecks in durability, dosing and toxicity helping to develop more effective neoantigen based therapies and vaccines
- Rational neoantigen based **combination strategies** and clinical **trial design** considerations to unleash the full therapeutic potential of this drug class across oncology indications
- Elucidating the desired immune response that translates into long term clinical **efficacy** in both personalised and off-the-shelf neoantigen vaccines
- Strategies to enhance time and cost-effectiveness of producing neoantigen vaccines and therapies for **streamlined translation** into the clinic

Join 75+ Directors, VPs and C-level executives in **cancer vaccines**, **immunotherapies** and **neoantigen R&D** at this translational forum for 3-days of hyper-relevant scientific learning and networking opportunities. Don't miss your chance to stay at the forefront of the neoantigen field and power the progression of your pipelines into clinically successful therapies.

What's On in 2025?

75+ Attendees

24+ Expert Speakers

16+ Data-Driven Presentations

3 Interactive Workshops

1 Scientific Poster Session

KEY BENEFITS OF ATTENDING

Power the progression of your neoantigen pipeline into efficacious therapies, with lessons from the clinic to develop robust protocols and identify appropriate patient populations with **Transgene**, **Nouscom** & **Geneos Therapeutics**

Expand your immune monitoring toolbox to accurately measure patient immune response and safeguard the development of durable, tolerable and targeted therapies with **Precision Biologics**, **Evaxion Biotech** & **Institut Curie**

Maximise the immunogenicity of your neoantigen cancer vaccines and therapies by establishing consensus on identifying and selecting immunogenic neoantigens with **AstraZeneca**, **CureVac** & **Anocca**

Achieve the full therapeutic potential of neoantigen vaccines and therapies by exploring synergistic combination strategies to overcome tumour resistance and enhance clinical efficacy with **Scancell** & **VacV Biotherapeutics**

Unlock neoantigen therapies for more patients by exploring shared neoantigens, evaluating the advantages of off-the-shelf therapies, and improving time and cost-efficiency of producing individualised therapies with **Genevation**, **Epitopea**

+44 (0)20 3141 8700 info@hansonwade.com
www.neoantigen-summit.com
hansonwade

What's New for 2025?

8th Annual International Neoantigen Summit
24th-26th June | Amsterdam, Netherlands

Brand-New Speaking Companies & Research Institutions

AMAL Therapeutics
AstraZeneca
GENEVATION LTD
GSK
GRIT Biotechnology 沙砾生物
HERVOLUTION THERAPEUTICS
institut Curie
NEOGAP
NEOMATRIX
SCANCELL USING IMMUNOLOGY TO FIGHT CANCER
VacV BTX

Unmissable Sessions

Roundtable Discussion: Lessons on Clinical Design, Patient Selection & Measuring Efficacy From Clinical Stage Trials

Ulrike Gnag-Vogt, Senior Vice President, Clinical Development, **CureVac**

Nous-209 Vaccine: From Cancer Treatment to Interception in Lynch Syndrome Patients

Morena D'Alise, Senior Vice President, Immunology, **Nouscom**

UNPUBLISHED DATA

BNT221: A First-in-Human Trial With a Personalised, Autologous Neoantigen-Specific T Cell Therapy in Metastatic Melanoma

Sebastian Klobuch, Medical Oncologist, **Netherlands Cancer Institute**

Phase 2 Study of AI-Designed Personalised Neoantigen Cancer Vaccine, EVX-01, in Combination With Pembrolizumab in Advanced Melanoma

UNPUBLISHED DATA

Daniela Kleine-Kohlbrecher, Project Director, Immuno-Onclology, **Evaxion Biotech**

Your Expert Speakers

Alastair Hay
Vice President, Peptides
Almac

Marie-Laure Santiago Raber
Chief Scientific Officer
AMAL Therapeutics

Reagan Jarvis
Chief Executive Officer
Anocca

Robbert Spaapen
Associate Director
AstraZeneca

Linda Gombos
Vice President, Manufacturing Science & Technology
Biomay

Helena Sabata
Business Development Manager
BCN Peptides

Katka Franke
Senior Director, Cancer Antigen Discovery & Validation
CureVac

Ulrike Gnad-Vogt
Senior Vice President, Clinical Development
CureVac

Klaus Edvardsen
Chief Medical Officer
Epitopea

Daniela Kleine-Kohlbrecher
Project Director, Immuno-oncology
Evaxion Biotech

Jian Yan
Vice President, Research & Discovery
Geneos Therapeutics

Prasun Chakraborty
Chief Executive Officer & Founder
Genevation

Jingwei Sun
Vice President, Research & Development
Grit Biotechnologies

Vanesa Bol
Director, Head of Systems Vaccinology
GSK

Peter Holst
Chief Scientific Officer
Hervolution Therapeutics

Olivier Lantz
Head of the Hospital Clinical Immunology Laboratory, Group Leader
Institut Curie

Christian Stumpp
Head of Marketing & Business Development
Intavis

Ola Nilsson
Head of Neoantigen Production, Development & Clinical Processing
NEOGAP Therapeutics

Heinz Lubenau
Chief Executive Officer
NEC Bio Therapeutics

Luigi Aurisicchio
Chief Executive Officer
Neomatrix

Sebastian Klobuch
Medical Oncologist
Netherlands Cancer Institute

Morena D'Alise
Senior Vice President, Immunology
Nouscom

Christelle Johnson
Director, Field Applications Scientist
Personalis

Philip Arlen
Chief Executive Officer
Precision Biologics

Nermeen Varawalla
Chief Medical Officer
Scancell

Maurizio Ceppi
Chief Scientific Officer
Transgene

Heather Shaw
Consultant Medical Oncologist
University College Hospital London & Mount Vernon Cancer Centre

Yaohe Wang
Chief Executive Officer
VacV Biotherapeutics

Pre-Conference Workshop Day

Tuesday, 24th June, 2025

8th Annual International Neoantigen Summit

24th-26th June | Amsterdam, Netherlands

Check In & Light Breakfast 8.00

Workshop A 9.00

Identifying Rational, Synergistic Neoantigen Combination Strategies to Maximise Clinical Efficacy & Overcome Tumour Resistance to Improve Patient Response Rate

Helping the industry to overcome challenges in efficacy and tumour resistance, combination strategies have been hailed the future of immunotherapy, with neoantigen-targeted cell therapies and vaccines increasingly being administered alongside other immunotherapies. However, navigating the complexity of administering multiple drugs requires smart protocol design, identification of distinct biomarkers, careful monitoring of toxicity, and precise assays to elucidate the effect of each therapy.

This workshop will cover:

- Understanding the limitations of neoantigen monotherapies and identifying the most rational, synergistic combination strategies
- How to optimise patient selection based on individual patient and tumour characteristics and immunopeptidomic data
- How to schedule administration, determine dosing, and monitor toxicity in patients to maximise efficacy and tolerability of neoantigen-targeted therapy combinations
- Effectively monitoring immune response and identifying unique biomarkers to elucidate the effect of each individual therapy to determine synergy versus independent action

Workshop Leaders

Nermeen Varawalla
Chief Medical Officer
Scancell

Yaohe Wang
Chief Executive Officer
VacV Biotherapeutics

Morning Break & Networking 11.00

Workshop B 11.30

Eliciting the Desired Immune Response for Long Term Clinical Efficacy in Both Personalised & Off-The-Shelf Neoantigen Cancer Vaccines & Cell Therapies

When monitoring the effect of neoantigen therapies, it is important to understand whether observed immune responses will lead to tumour regression. Additionally, determining how targeted neoantigens are actually processed and presented on tumours is vital to ensure the most appropriate neoantigen targets are selected. Furthermore, selecting the right patients, indications, and conditioning regimen to maximise clinical success is necessary to increase the likelihood of an efficacious clinical response.

This workshop will address:

- Identifying an appropriate patient population based on patient and tumour characteristics to ensure the right patients are being treated at the right time
- Understanding at which line of treatment to administer neoantigen-based therapies, and which disease types are most responsive to treatment
- Selecting the right therapeutic platform and conditioning regimen for patients depending on their level of immune depletion to enhance therapeutic tolerability and achieve long-term efficacy
- Determining desired level of therapeutics efficacy and selecting appropriate read outs and end points to measure clinical success

Workshop Leaders

Heather Shaw
Consultant Medical Oncologist
University College Hospital London & Mount Vernon Cancer Centre

Olivier Lantz
Head of the Hospital Clinical Immunology Laboratory, Group Leader
Institut Curie

Lunch Break & Networking 13.30

+44 (0)20 3141 8700 info@hansonwade.com
www.neoantigen-summit.com

hansonwade

Workshop C — 14.30

How Personalised Should Neoantigen-Targeted Cell Therapies & Cancer Vaccines Be? Unravelling the Limitations of Precision Neoantigen Therapies & Exploring Shared-Neoantigens for an Off-The-Shelf Approach

Personalised therapies hold promise to provide the most optimal treatment plan available to patients, overcoming tumour heterogeneity and resistance. However, identifying specific neoantigens and developing precision therapies incurs a high cost, complex logistical planning, and a lengthy timeframe which is often too great for patients with late-stage disease. As such, the feasibility and scalability of personalised therapies is uncertain.

Identifying shared neoantigens and developing off-the-shelf neoantigen therapies for small groups of patients could help overcome these challenges. Can allogenic therapies hold up against the precision of personalised therapies?

This workshop will delve into:

- The feasibility and scalability of personalised neoantigen therapies, considering the expense and logistics of manufacturing therapies for one person, the cost on patient health of delaying treatment, and health equity
- Identifying shared neoantigens and hotspot mutations in subsets of patients for the development of small-group off-the-shelf neoantigen vaccines and cell therapies
- Should neoantigen therapies be developed for individuals, small groups with shared neoantigens, or be truly off-the-shelf?

Workshop Leaders

Robbert Spaapen
Associate Director
AstraZeneca

Klaus Edvardsen
Chief Medical Officer
Epitopea

End of Pre-Conference Workshop Day — 16.30

> "The value of participating in the meeting is the opportunity for open exchange of scientific concepts and ideas, and meeting industry and academic colleagues who all share the same goal, to improve life and health of cancer patients"
>
> Senior Director, **CureVac**

Conference Day One
Wednesday, 25th June, 2025

7:30 Check In & Light Breakfast

Vanesa Bol
Director, Head of Systems Vaccinology
GSK

8:20 **Chair's Opening Remarks**

Highlighting Clinical Updates of Neoantigen-Targeted Vaccines & Cell Therapies & Utilising Lessons Learnt to Facilitate Future Clinical Progression

Morena D'Alise
Senior Vice President, Immunology
Nouscom
UNPUBLISHED DATA

8:30 **Nous-209 Vaccine: From Cancer Treatment to Interception in Lynch Syndrome Patients**

- Presenting NOUS-209, an off-the-shelf cancer vaccine encoding shared neoantigens across both sporadic and hereditary Microsatellite Instable (MSI) tumours
- Showing strong immunogenicity, breadth and durability of NOUS-209 induced immune response in patients with metastatic MSI tumours and Lynch Syndrome (LS) vaccinated patients
- Highlighting NOUS-209 Potential to 'Intercept' Cancer in Subjects with LS

Daniela Kleine-Kohlbrecher
Project Director, Immuno-oncology
Evaxion Biotech
UNPUBLISHED DATA

9:00 **Phase 2 Study of AI-Designed Personalised Neoantigen Cancer Vaccine, EVX-01, in Combination With Pembrolizumab in Advanced Melanoma**

- Discussing AI designed personalised peptide vaccines
- Understanding the phase 2 clinical testing
- Considering antigen specific T-cell responses and Biomarker analysis

Jian Yan
Vice President, Research & Discovery
Geneos Therapeutics
UNPUBLISHED DATA

9:30 **Personalised DNA Therapeutic Cancer Vaccines: Clinical Efficacy & Mechanism of Action**

- Reviewing updated clinical efficacy data from patients treated with personalised DNA therapeutic cancer vaccines
- Considering the mechanism of action
- Discovering Immune correlation and biomarker analysis

Christian Stumpp
Head of Marketing & Business Development
Intavis

10:00 **Accelerating Personalized Peptide Vaccine Trials**

- What are current challenges when conducting trials on personalized peptide vaccines?
- How do you choose the right CDMO to meet those challenges?

10:10 **Morning Break & Speed Networking**

This is your opportunity to connect with global neoantigen leaders, make meaningful industry connections and share learnings and ideas to drive the future of neoantigen therapy.

Advancing the Identification & Selection of Immunogenic Neoantigens for Durable Immune Response & Disease Regression in Patients

Robbert Spaapen
Associate Director
AstraZeneca

11.00 **Neoantigen-specific TCR discovery at AstraZeneca**

- Introducing our personalized neoantigen-specific TCR discovery platform
- Demonstrating extensive validation and application of TCRs identified through our platform
- Showcasing AZ strategies to armor TCR-T cell products for use in clinical trials

Jingwei Sun
Vice President of Research & Development
Grit Biotechnology

11.30 **Development of Next-Generation Neoantigen Cancer Vaccine With a Functional Discovery Platform & APC-Targeted LNP System**

- Overviewing the development of a neoantigen discovery platform that integrates an AI algorithm deeply investigating the characteristics of neoantigens with validated immunogenicity using tumour-specific T cells derived from autologous TILs and PBMCs
- Evaluating delivery via an APC-targeted LNP system, the neoantigen cancer vaccine induced robust antigen-specific T-cell responses and effectively controlled tumours in multiple mouse tumour models
- Discussing an investigator-initiated clinical trial is set to begin in China

Christelle Johnson
Director, Field Applications Scientist
Personalis

12.00 Personalis NeXT Platform: Precision Neoantigen Selection and MRD Detection

The Personalis NeXT Platform integrates deep tumor tissue profiling with ultrasensitive plasma-based monitoring to support neoantigen-based immunotherapy development.

- ImmunoID NeXT delivers comprehensive immunogenomic profiling from tumor tissue, enabling accurate neoantigen selection through validated exome/transcriptome assays, and neoantigen predictions trained on immunopeptidomics data
- NeXT Personal is a tumor-informed, plasma-based assay for detecting molecular residual disease and recurrence earlier, with longitudinal variant tracking for real-time insight into disease progression
- Together, these assays provide a unified view from tumor to circulation, enhancing precision oncology strategies

12.30 Panel Discussion: Validating Immunogenicity of Neoantigens & Establishing a Consensus on Selecting Optimal Neoantigen Targets to Generate an Efficacious Immune Response

- Developing a robust, functional validation platform using effector T-cells to validate neoantigen immunogenicity and avoid systemic toxicity
- Establishing a consensus on the most appropriate tools and technologies for ranking and selecting the best neoantigens for targeting
- Characterising neoantigens and selecting an appropriate number for use in therapies to invoke immunogenicity in patients

Jingwei Sun
Vice President of Research & Development
Grit Biotechnology

Reagan Jarvis
Chief Executive Officer
Anocca

Klaus Edvardsen
Chief Medical Officer
Epitopea

Katka Franke
Senior Director Cancer Antigen Discovery & Validation
CureVac

Helena Sabata
Business Development Manager
BCN Peptides

13:00 BCN Peptides: Cutting-Edge Technology for the Manufacturing of Personalized Neoantigen Peptide Therapies

- BCN Peptides is a European privately held company focused on the GMP industrial manufacture of bioactive peptides. Our Peptide-based Personalized Medicine Laboratory (PPM Lab) has been designed and equipped with state-of-the-art technology
- Our software enables full GMP control through online management of sequences, real-time process monitoring, and automatized revision and CoA issuance
- Peptide-based anticancer vaccination has proven the ability to induce cancer-specific immune responses and allows the production of safe and effective individualized neoantigen peptide therapies

13:10 Lunch Break & Networking

Optimising Preclinical Development of Investigational Neoantigen Therapies for Streamlined Entry Into the Clinic & Accelerated Regulatory Approval

Marie-Laure Santiago Raber
Chief Scientific Officer
AMAL Therapeutics

UNPUBLISHED DATA

14:10 A Heterologous Prime-Boost Vaccination With a Peptide-Based Vaccine & Viral Vector Improves Antitumour Therapy in Preclinical Models. Maximise the Potential of *In Vivo* Studies to Validate a Platform Preclinically & Prepare for Regulatory Interactions

- Investigating regimen, combination and vaccine MoA supported by preclinical studies
- Harnessing preclinical models to study changes in the tumour microenvironment and T-cell function after vaccination

Heinz Lubenau
Chief Executive Officer
NEC Bio Therapeutics

14:40 NECVAX-NEO1, an Oral Bacteria-Based Personalized Neoantigen Vaccine in Combination with Checkpoint Inhibitor in Solid Tumor Patients

- NEC's proprietary AI-based neoantigen identification and ranking
- Fast and efficient manufacturing process
- Mechanism of action and study design
- Immune biomarker strategy and clinical data

Conference Day One
Wednesday, 25th June, 2025

Olivier Lantz
Head of the Hospital Clinical Immunology Laboratory, Group Leader
Institut Curie

14:50 **From the Discovery & Validation of Public Tumour-Specific Neoantigen Derived From the Dark Genome to a Clinical Trial in Uveal Melanoma: An Academic Perspective**

- How to test immunogenicity: in healthy donors, in patients or in preclinical models? What level of preclinical validation?
- Refining early phase testing: vaccine alone or in association with immunomodulators? Which one? Which schedule?
- Discussing primary objectives: CD4 and CD8 responses instead of clinical response. Which methods? How to monitor the Treg response?

15:20 **Afternoon Break & Poster Session**
Take this opportunity to showcase your latest neoantigen data and innovations with your peers and understand the strategies of your fellow neoantigen experts.

Rethinking Clinical Trial Design to Optimise Patient Selection, Administer Neoantigen Therapies in the Correct Setting & Appropriately Determine Clinical Success

Ulrike Gnad-Vogt
Senior Vice President, Clinical Development
CureVac

16.00 **Roundtable: Lessons on Clinical Design, Patient Selection & Measuring Efficacy From Clinical Stage Trials**

- Designing clinical trials to meet regulatory approval with thoughtful protocol design, patient selection and management of toxicity
- Measuring and recording patient immune response and clinical efficacy
- Selecting measures of success, from levels of efficacy to tumour regression

Nermeen Varawalla
Chief Medical Officer
Scancell

16:30 **Smart Design of Neoantigen Vaccine Clinical Development**

- Selecting the cancer type, disease setting and patient subpopulation
- Determining dosing schedules, mode of administration and alignment with standard of care
- Deciding on endpoints of immune and clinical response to demonstrate improvements over standard of care

Sebastian Klobuch
Medical Oncologist
Netherlands Cancer Institute

17:00 **BNT221: A First-in-Human Trial With a Personalised, Autologous Neoantigen-Specific T Cell Therapy in Metastatic Melanoma**

- Understanding BNT221 Mechanism and Study Design – A personalized, neoantigen-specific autologous T cell therapy tested in a dose-finding study for advanced melanoma refractory to immune checkpoint blockade and BRAF-targeted therapy
- Navigating Safety and Tolerability – Well tolerated across doses with no severe toxicities; no cytokine release syndrome or neurotoxicity observed. Optimal dose range identified for further studies
- Evaluating Clinical and Immune Response – Six patients achieved stable disease, with some tumor reduction; strong neoantigen-specific CD4+/CD8+ T cell responses detected in blood and tumor

17:30 **End of Conference Day One**

Conference Day Two
Thursday, 26th June, 2025

7:50 Check In & Light Breakfast

Katka Franke
Senior Director Cancer Antigen Discovery & Validation
CureVac

8.50 **Chair's Opening Remarks**

Unleashing the Full Therapeutic Impact of Neoantigen-Targeted Cancer Vaccines With Optimised Design & Delivery to Invoke a Durable Immune Response

Prasun Chakraborty
Chief Executive Officer
Genevation
UNPUBLISHED DATA

9.00 **Revolutionising Cancer Treatment: AI-Driven Personalised Vaccines**

- Introducing AI-mediated personalised cancer vaccine platform
- Overviewing the proprietary neoantigen identification process that reduces development time to two weeks
- Implementing competitive differentiation through AI-driven vaccine design and rapid deployment

Alastair Hay
Vice President, Peptides
Almac

9.30 **Latest advances in peptide manufacture supporting Neoantigen programmes**

- Trends in requirements for peptide-based vaccines and cell therapies
- Process flow pinch-points and how they are solved

Maurizio Ceppi
Chief Scientific Officer
Transgene

9.40 **Personalised Cancer Vaccine TG4050 in Resected Locally Advanced Head & Neck Squamous Cell Carcinoma (HNSCC) Patients**

- Reviewing TG4050, an individualised immunotherapy being developed for solid tumours that is based on Transgene's myvac® technology and powered by NEC's longstanding artificial intelligence (AI) and machine learning expertise
- Discussing how TG4050 is being evaluated in a randomised multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers
- Assesing 24-month follow up clinical and translational data from patients enrolled in the Phase I trial will be presented

10:10 Morning Break & Networking

Reaching the Full Therapeutic Potential of Neoantigen-Targeted Cell Therapies & Beyond to Improve Patient Outcome

Yaohe Wang
Chief Executive Officer
VacV Biotherapeutics
UNPUBLISHED DATA

11.00 **A Personalised Neo-antigen Viro-Immunotherapy Platform for Human Solid Tumours**

- How to identify immunogenic neoantigen epitopes? Is computational prediction sufficient?
- How to optimise tumour-targeted replicating oncolytic virus to unlock the power of virotherapy for cancer treatment?
- How to combine oncolytic viruses and neoantigens as a synergistic frontier for cancer treatment?

Ola Nilsson
Head of Neoantigen Production, Development & Clinical Processing
NEOGAP Therapeutics
UNPUBLISHED DATA

11:30 **A First-in-Human Phase I/IIa Trial of Personalised Tumour-Trained Lymphocytes (pTTL) Derived From Regional Lymph Nodes for the Treatment of Colorectal Cancer**

- Examining pTTL (personalised Tumour-Trained Lymphocytes), a novel adoptive T-cell therapy product targeting tumour neoantigens. It is applicable to any cancer type for which neoantigens can be identified
- Understanding how therapy is personalised, tailored for the patient's own tumour and consists of autologuous neoantigen selected T-cells derived from regional lymph nodes (RLN)
- Unveiling a first-in-human trial of pTTL in stage IV colorectal cancer is ongoing

Conference Day Two
Thursday, 26th June, 2025

Peter Johannes Holst
Chief Scientific Officer
HERVolution Therapeutics

12:00 Targeting Cancer & Senescence Associated HERVs With mRNA & Adenovirus Encoded Antigens

- Discussing human endogenous retroviruses (HERVs) as emerged as possible immunotherapeutic targets for cancer and cell senescence associated diseases
- Reviewing how HERVOLUTION have developed mRNA and viral vector delivered HERV antigens forming HERV-like-particles within transduced cells
- Examining unique immunostimulatory mutations and viral chimerism allows effective break of immunological tolerance and anti-cancer and senolytic efficacy

12:30 Lunch & Networking

Optimising Manufacturing Efficiency of Neoantigen Therapies to Facilitate the Rapid Administration of High-Quality Therapies to Patients

Luigi Aurisicchio
Chief Executive Officer
Neomatrix

1:30 Neomatrix: An Innovative, Fully-Synthetic DNA Platform for Next Generation Cancer Vaccines

- Evaluating how neoantigen identification is key for the design of personalised cancer vaccines and the requirements of prediction algorithm
- Enhancing a fast and reliable manufacturing technology and how synthetic DNA allowed the production of NCV in few days, without complex upstream and downstream procedures
- Investigating a efficient delivery method by using Electroporation which enhances gene expression and acts as adjuvant of immune response

Linda Gombos
Vice President, Manufacturing Science & Technology
Biomay

UNPUBLISHED DATA

14:00 High-Throughput Manufacturing of Personalized Plasmid DNA Cancer Vaccines

- Introducing a high-throughput manufacturing platform for personalized plasmid DNA, which has been used to manufacture >100 batches
- Enhancing process performance by process optimization and adequate analytical portfolio
- Discussing approaches to facility design, evaluation of trending data to monitor manufacturing performance etc. to ensure a small footprint, rapid turnaround times and cost effectiveness

Prasun Chakraborty
Chief Executive Officer & Founder
Genevation

14:30 Roundtable Discussion: Leveraging Technological Advances, Novel Manufacturing Approaches & External Partners to Safeguard Production Timeliness & Enhance the Quality of Autologous Neoantigen Therapies

- Considering manufacturing and quality control testing of personalised neoantigen platforms to guide platform choice for autologous therapies
- Turning to novel manufacturing technologies such as cell-free DNA production for rapid therapeutic manufacture whilst maintaining purity and regulatory adherence
- Evaluating quality, production efficiency and cost of external suppliers to make informed partnering decisions

15.00 Afternoon Break & Networking

Conference Day Two
Thursday, 26th June, 2025

Spotlighting Advances in Immune System Monitoring to Facilitate Accurate, Real-Time Understanding of Patient Response & Therapeutic Effect

15.45 Fireside Chat: Creating Alignment in Immune Monitoring & Interpretation of Read Outs to Increase Investment Opportunities & Accurately Measure Clinical Efficacy

- Creating a robust, methodical protocol for monitoring and analysing immune response to enable investors to contextualise and compare therapeutic efficacy
- Ensuring appropriate read outs and biomarkers are selected for immune monitoring to accurately evaluate immunogenicity of neoantigen vaccines and cell therapies
- Determining a desired level of de novo and secondary immune response to quantify efficacy

Olivier Lantz
Head of the Hospital Clinical Immunology Laboratory, Group Leader
Institut Curie

Philip Arlen
Chief Executive Officer
Precision Biologics

Philip Arlen
Chief Executive Officer
Precision Biologics

16.15 Reduction of Circulating Naïve Tregs & gMDSCs Mediated by NEO-201 & Low Levels of Soluble MICA are Prognostic Factors for Efficacy of Combined Treatment With NEO-201 & Pembrolizumab in Adults With Solid Tumours Resistant to Prior Checkpoint Inhibitors

- Examining the Accumulation of immunosuppressive cells in the TME, such as Tregs and gMDSCs is one of the mechanisms of tumour resistance to checkpoint inhibitors
- Understanding how NEO-201 mediates the killing of targets cells expressing core 1 O-glycans (including cancer cells and immunosuppressive cells) through ADCC and CDC. Elimination of circulating gMDSCs and Tregs mediated by NEO-201 may overcome resistance to checkpoints inhibitors
- Discussing levels of immunosuppressive cells and soluble factors that affect NK cells cytotoxic activity after treatment with NEO-201 can be used as prognostic factors for the efficacy of treatment with NEO-201 alone or in combination with other anti-cancer drugs

16:45 End of Conference Day Two

2025 Partners

Expertise Partner:

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

www.personalis.com

Innovation Partner:

Almac has been supplying peptides to the research community and for clinical trials for > 20 years. The field of personalised cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs. Think Almac for peptide excellence.

www.almacgroup.com

Innovation Partner:

Your trusted end-to-end provider of personalized peptide cancer vaccines with 30+ years in peptide synthesis. With expanding facilities for GMP peptide manufacturing and aseptic fill and finish, we offer full peptide drug development: customized researchgrade peptides, peptide drug substance and peptide drug product. In combination with our unmatched customer-service and manufacturing speed, you will execute your personalized vaccine trial faster with less worries. Simply contact us for a truly end-to-end peptide trial solution.

www.intavispeptides.com

Innovation Partner:

BCN Peptides is a leading European manufacturer specializing in the cGMP production Peptides with a strong commitment to quality and innovation, we provide tailored solutions to meet the evolving needs of the industry.

Peptides for Personalized Medicine
We produce small-scale GMP peptides dedicated to single-patient treatments, offering a cutting-edge approach to API production that aligns with the latest industry and regulatory standards.

API Peptide Synthesis
Using state-of-the-art SPPS technology, we manufacture peptide APIs from milligrams to multi-kilo commercial batches. Our GMP compliance is recognized by PMDA, US-FDA, and EDQM approvals, ensuring excellence at every stage of production. Delivering high-quality peptide solutions to drive innovation in healthcare.

www.bcnpeptides.com

GET INVOLVED

Finlay Coombes
Business Development Manager
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

2025 Partners

Innovation Partner:

NEC Bio is a clinical stage biotech company developing cutting-edge personalized cancer treatments and universal infectious disease vaccines. NEC Bio operates under the umbrella of NEC Corporation - a notable ICT conglomerate in Japan. For over a decade, NEC's top-tier AI technology, on par with industry giants like Google, is applied in critical security systems globally, including facial recognition used in border control and law enforcement.

NEC's proprietary, cutting-edge neoantigen prediction system, the NEC Immune Profiler, takes a holistic approach to the personalized cancer vaccine problem, combining transcriptomic, proteomic and other data to model all the steps in the T cell priming pathway to identify truly immunogenic neoantigens.

www.nec-bio.com

Innovation Partner:

Biomay is an innovative **GMP CDMO** for manufacturing of **plasmid DNA, recombinant proteins and mRNA**. Biomay **offers off-the-shelf products** (AAV/LV plasmids and Cas9 nuclease) as well as customized product manufacturing.

Biomay has a strong track record in GMP manufacturing of advanced therapeutics (ATMPs), such as DNA vectors for cell and gene therapies, used as starting plasmids for viral vectors (AAV) or as mRNA-IVT templates, or as non-viral drug substances and personalised medicine vectors.

Biomay has also a wide experience in GMP manufacturing of different recombinant proteins, including recombinant nuclease Cas9 for gene editing (US late stage project, FDA inspected). To complement our manufacturing services for the gene therapy community, we offer also mRNA production based on in-vitro transcription (IVT). Biomay´s CMO services comprise process and analytical development, cell banking, GMP manufacturing of drug products and drug substances and analytical testing services. The company also offers Aseptic Filling services.

Biomay is operating its brand-new manufacturing facility, with bioreactor capacities from 5 L to 750 L (microbial based).

www.biomay.com

Exhibition Partner:

Alithea empowers biopharma with the world's most advanced HLA-peptide data platform to accelerate neoantigen discovery, validation, and safety profiling. Our end-to-end solution transforms patient samples into actionable insights using proprietary mass spectrometry, AI, and Big Data. By bridging cutting-edge science with scalable technology, we enable the development of highly personalized and effective cancer therapies—faster and safer. Alithea makes precision oncology a reality.

www.alithea-bio.com

GET INVOLVED

Finlay Coombes
Business Development Manager
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Partner With Us

8th Annual International Neoantigen Summit
24th-26th June | Amsterdam, Netherlands

Are you dedicated to supporting the development of tolerable, durable and efficacious neoantigen based cancer vaccines and cell therapies?

Returning to Amsterdam, the 8th International Neoantigen Summit is your unique opportunity to connect with decision makers actively looking for innovative solutions to progress their neoantigen pipelines.

Our C-suite audience have expressed an explicit need for services including **antigen discovery**, **peptide services**, **sequencing**, **manufacturing** and **clinical trial design**.

Gathering at the only global touchpoint, neoantigen experts want to hear how they can be supported to streamline the development and production of cancer vaccines and cell therapies. Will you be joining them?

Position yourself as the go-to industry expert

Connect directly with your target expert audience and establish yourself as the leading solution provider in the neoantigen space

Gain exclusive first-hand market insights

Hear the latest data and understand pain points directly from the industry to put yourself a step-ahead of the trends

Build meaningful connections with neoantigen leaders

Enjoy 7+ hours of networking time to build important industry relationships and establish your next partnership

Amplify your brand to the neoantigen community

Take advantage of our branding opportunities and share your newest data to create a lasting impression of your solutions and services

SENIORITY OF ATTENDEES*



- Director / VP / Head – 33%
- CXO – 30%
- Other – 22%
- Scientist & Academics – 15%

TYPES OF COMPANIES ATTENDING*



- Drug Developers
- Research Institute
- Healthcare Providers
- Equipment & Service Provider

Statistics taken from 7th International Neoantigen Summit

GET INVOLVED

Finlay Coombes
Business Development Manager
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.neoantigen-summit.com/take-part/register/

Tel: +44 (0)20 3141 8700

Email: info@hansonwade.com

Transform your neoantigen selection strategy to identify the most immunogenic neoantigens, ensuring your neoantigen cancer vaccines and cell therapies induce a durable immune response.

Discover the latest clinical updates and protocol design considerations to advance your neoantigen pipeline and drive the development of clinically successful neoantigen therapies.

Power the development of efficacious cancer vaccines and cell therapies by exploring rational combination strategies to overcome tumour resistance.

Drug Developer Pricing*	Register & Pay By Monday, 23rd June to Save	On the Door Price
Conference + Workshop Day	€3,697 (€100 Savings)	€ 3,797
Conference Only	€2,699 (€100 Savings)	€ 2,799
Academic Pricing **	Register & Pay By Monday, 23rd June to Save	On the Door Price
Conference + Workshop Day	€3,097 (€100 Savings)	€ 3,197
Conference Only	€2,299 (€100 Savings)	€ 2,399
Solution & Service Provider Pricing	Register & Pay By Monday, 23rd June to Save	On the Door Price
Conference + Workshop Day	€4,497 (€100 Savings)	€ 4,597
Conference Only	€3,299 (€100 Savings)	€ 3,399

To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending Please note: If you are a UK or EU-based company, you may be subject to a 20% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout

Team Discounts**

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4 + Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Steigenberger Airport Hotel Amsterdam

Stationsplein Zuid-West 951, 1117 CE Schiphol, Netherlands

www.hrewards.com/en/steigenberger-airport-hotel-amsterdam

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom